Genetic Technologies Limited (ASX: $GTG) has revealed a significant distribution agreement with Stayhealthy, Inc. to introduce the innovative Multi-Risk Test to a wider audience in the online pharmacy channel across North America. This collaboration aims to empower individuals to take charge of their health through accessible health risk assessments.
Partnering with GeneType allows us to reach more people with Gene Types Multi-Risk Test, offering a powerful tool for health management. Genetype's expertise in non-invasive genetic testing complements our technology perfectly. - John Collins, CEO of Stayhealthy
Genetic Technologies (ASX: $GTG) has entered into a landmark distribution agreement with Stayhealthy, Inc. to expand the reach of the Multi-Risk Test in North America. This strategic partnership aims to provide individuals with comprehensive insights into their health risks and actionable steps to mitigate them. The collaboration reflects Genetic Technologies' commitment to enhancing health outcomes and empowering individuals to make informed health decisions. The company's continued focus on developing risk assessment products underscores its dedication to advancing health and wellness solutions. The partnership with Stayhealthy aligns with Genetic Technologies' goal of leveraging technology to improve health outcomes and underscores its position as a global leader in genomics-based tests for health, wellness, and serious disease.